Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07470606

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues.

The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Mays Cancer Center, UT Health San Antonio

San Antonio, Texas, 78229, United States

Location contact

Andrew J Brenner, MD, PhD

PRINCIPAL_INVESTIGATOR

Eva M Galvan, MD

PRINCIPAL_INVESTIGATOR

Kayla Chamberlain

CONTACT

[email protected]

210-450-5964

About this study

As cognitive decline is a common side effect after external beam radiation therapy to the brain, estrogen receptor beta (ERβ) modulation presents an unexploited target for mitigating this adverse effect as well.

The investigators seek to address two scientific questions to improve quality of life in patients and improve cancer outcomes: 1) can estrogen modulation further augment neuroprotection achieved by memantine after radiation therapy to the brain? and 2) can estrogen modulation lead to measurable tumor control improvement and molecular changes in CNS malignancies?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Ability to provide informed written consent in either English or Spanish.
  • All individuals of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an Intrauterine device (IUD)) with their partner from entry into the study through 24 weeks after the last dose of Raloxifene.
  • Patients undergoing radiation therapy to the brain as a part of solid tumor cancer therapy, using intensity modulated radiation therapy (IMRT) or whole brain radiation therapy (WBRT).Willingness to adhere to planned study drug regimen, including obtaining medication from an outside pharmacy via prescription.
  • Patients must have a creatinine clearance ≥ 50 mL/min (using Cockcroft-Gault Equation).
  • Patients must not have hepatic impairment greater than Child-Pugh Score "Class A".

Exclusion criteria

  • History of prior radiotherapy to the brain.
  • Life expectancy of < 6 months.
  • Radiation Therapy planned is ≤ 5 fractions (e.g.stereotactic radiosurgery (SRS)or Steriotactic radiotherapy (SRT), or 5-fraction whole brain).
  • Contraindications to taking memantine and/or raloxifene based on package inserts and the clinical judgement of the treating physician .
  • The subject is unable to undergo magnetic resonance imaging (MRI) scan (e.g., has an MRI incompatible pacemaker).
  • Conditions or situations which, in the opinion of the investigator, imply the patient will be unable or not suitable to complete trial requirements or at excessive risk from trial participation.
  • Known allergy to either of the medications (Memantine or Raloxifene) used in this study or their excipients.
  • Cognitive failure as assessed by Mini Mental State Exam (MMSE) score <17

Treatment and study plan

Memantine

Drug

The goal dose for Immediate Release Memantine is 10 mg oral twice daily. The goal-dose for Extended-Release Memantine is 21 mg daily.

Other names: Namenda

Raloxifene

Drug

Raloxifene will be administered at 120mg orally every day

Other names: Evista

Primary outcomes

  1. Hippocampal volume changes

    Time frame: Baseline to 48 weeks

    MRIs will be used to capture any changes in hippocampal volume

Secondary outcomes

  1. Eastern Cooperative Oncology Group Performance Status score

    Time frame: Baseline to study termination visit (approximately 48 weeks)

    A 0-5 scale to assess a cancer patient's functional ability showing how their daily life is impacted by the disease. A score of 0 means fully active, while a higher score indicates increasing disability with 5 indicating death.

  2. Hopkins Verbal Learning Test Revised (HLVT-R) Score

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    HVLT-R scoring involves summing words recalled in learning trials for Total Recall, calculating Percentage Retention (Delayed Recall / Higher of Trials 2/3), and determining the Recognition Discrimination Index (True Positives - False Positives). These raw scores are then converted to age-adjusted T-scores, which are compared to normative data (16-92 years old) to assess verbal learning and memory in brain-disordered populations, with higher scores generally indicating better performance.

  3. Trail Making Test -A (TMT-A) Score

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    A neuropsychological number test measuring psychomotor speed and visual attention by connecting numbers (1-25) in sequence. Higher scores (more time) indicate greater impairment, with averages around 29 seconds, while scores over 30-40 seconds often suggest potential cognitive issues, though norms vary by age and education.

  4. Trail Making Test -B (TMT-B) Score

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    A neuropsychological number and letter test measuring psychomotor speed and visual attention by connecting numbers (1-25) in sequence. Higher scores (more time) indicate greater impairment, with averages around 75 seconds, while scores over 273 second often suggest potential cognitive issues, though norms vary by age and education.

  5. Controlled Oral Word Association (COWA) Test Score

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    A neuropsychological test assessing verbal fluency and executive functions like self-initiation, requiring a person to name as many words as possible starting with a specific letter (like F, A, S, or C, F, L) within 60 seconds, for three trials, while avoiding repetitions, proper nouns, or variations of the same word root to gauge cognitive health, especially after brain injury or with conditions like dementia. The score includes the total number of unique, correct words across the trials. A higher score indicated better cognitive function.

  6. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Brain (BN)tumor-20

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    A 20 item questionnaire with each item scored from 0-4 with a total possible score of 0-80. A higher score indicates a worse quality of life.

  7. MD Anderson Symptom Inventory Brain Tumor (MDASI-BT)

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    Involves rating 23 symptoms and 6 interference items on a 0-10 scale (0=not present/did not interfere, 10=as bad as you can imagine/interfered completely) for the last 24 hours, calculating mean scores for overall symptoms, symptom factors (like neurological, cognitive, GI), and interference (activity/mood), with scores of 5 or greater indicating moderate-to-severe symptoms. Scores are averaged for summary measures, providing a picture of symptom burden and its impact on daily life for brain tumor patients. A mean of the total score is calculated with a higher score indicating worse symptoms.

  8. Functional Assessment of Cancer Therapy - Brain (FACT-Br)

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    A total of 50 items are included that cover the following domains of Quality of life (QOL): physical well-being, social/family well-being, emotional well-being, functional well-being, and disease specific concerns. Patients are asked to indicate the presence/severity of certain issues/symptoms on a scale of 0 - 4 (a 5-point Likert Scale).The range of scores is 0-148 with a higher indicating a better quality of life.

  9. Medical Outcomes Study - Cognitive Function (MOS-CF)

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    The Medical Outcomes Study Cognitive Functioning Scale is a patient-reported measure of perceived cognitive functioning consisting of six items that assess the frequency of problems with concentration, reasoning, confusion, forgetfulness, and mental clarity during the previous four weeks. Each item is scored on a 6-point Likert scale ranging from 1 ("all of the time") to 6 ("none of the time"), where higher values indicate fewer cognitive difficulties. Item scores are summed to generate a raw total score ranging from 6 to 36, with higher scores reflecting better cognitive functioning and fewer reported cognitive problems, and lower scores indicating greater perceived impairment. In some studies the raw score is also linearly transformed to a 0-100 scale, where 0 represents the worst cognitive functioning and 100 represents the best cognitive functioning.

  10. Patient Reported Outcomes Measurement Information System - Cognitive Function (PROMIS-CF)

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    The PROMIS-CF score is derived from two items: (1) My memory has been as good as usual and (2) I have been able to focus my attention, which ask patients to self-report on their cognitive abilities with the following response scale: 1 = Not at all, 2 = A little bit, 3 = Somewhat; 4 = Quite a bit, and 5 = Very much. Total scores are from 1-10 with a higher score indicating better cognitive function.

  11. Hopkins Verbal Learning Test Revised HLVT-R DR

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    Hopkins Verbal Learning Test-Revised Delayed Recall is a neuropsychological test assessing verbal memory by having individuals recall a list of 12 words after a delay (around 20-25 minutes). Scoring is from 0-12 with a higher score indicating better recall.

  12. Hopkins Verbal Learning Test Revised HLVT-R RECOG

    Time frame: Week 0 to study termination visit (approximately 48 weeks)

    The Hopkins Verbal Learning Test-Revised recognition discrimination index is a component of the HVLT-R that evaluates verbal recognition memory following presentation of a 12-word learning list. After the delayed recall phase, participants complete a recognition trial consisting of 24 items (the 12 original target words mixed with 12 distractor words). For each item, the respondent indicates whether the word was part of the original list (yes/no). Scoring is based on the Recognition Discrimination Index (RDI), calculated as the number of correct recognitions (hits) minus the number of incorrect endorsements of distractors (false positives). The resulting score ranges from -12 to +12, with higher scores indicating better recognition memory and greater ability to discriminate target words from distractors, while lower scores reflect poorer recognition performance and greater memory impairment.

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew J Brenner, MD, PhD

CONTACT

[email protected]

210-562-4090

Eva M Galvan, MD

CONTACT

[email protected]

210-450-1093

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center at San Antonio

Other

Registry information

Official study title

Memory RT: Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Acronym: MemoryRT

Important dates

Study start
2026
Primary completion
2030
Study completion
2031
First posted
Mar 13, 2026
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.